Mustang Bio (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S.[1][2][3] Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).
[5][7] In April 2017, Manuel Litchman took over as CEO of Mustang Bio, and in October of the same year, the company signed a lease with the University of Massachusetts Medicine Science Park in Worcester, MA, for a manufacturing facility to support the clinical development and commercialization of CAR-T products for glioblastoma and acute myeloid leukemia.
[6] After licensing a gene therapy for X-SCID from St Jude Children's Research Hospital, Mustang Bio expanded its efforts to immunodeficiency treatments.
[4][5] In April 2019, it was announced that the gene therapy developed by St. Jude's showed positive results in a trial involving eight infants suffering from X-SCID.
[5][7] In May 2019, Mustang Bio raised $32 million in an underwritten public offering to fund its continued development of products for the treatment of blood cancers, solid tumors, and rare genetic diseases.